Kyverna Therapeutics, Inc. Insider Trading Arrangements
Rule 10b5-1 and other trading arrangements that directors and officers adopted or terminated, as each 10-Q and 10-K tags them (Item 408(a)), newest report first.
- 2026-08-11: .
- 2026-05-12: .
- 2026-03-26: .
- 2026-03-26: Individual Warner Biddle; Title Chief Executive Officer; Arrangement Rule 10b5-1; Adopted December 2, 2025.
| Report filed | Individual | Title | Arrangement | Adopted | Terminated | Expires or duration | Securities covered |
|---|---|---|---|---|---|---|---|
| 2026-08-11 10-Q | |||||||
| 2026-05-12 10-Q | |||||||
| 2026-03-26 10-K | |||||||
| 2026-03-26 10-K | Warner Biddle | Chief Executive Officer | Rule 10b5-1 | December 2, 2025 | December 15, 2026 | 434,998 | |
| 2026-03-26 10-K | Beth Seidenberg, M.D | Director | Rule 10b5-1 | December 4, 2025 | August 3, 2026 | 1,250,020 | |
| 2025-11-12 10-Q | |||||||
| 2025-11-12 10-Q | Karen Walker | Chief Technology Officer | Rule 10b5-1 | September 12, 2025 | May 1, 2026 | 67,997 | |
| 2025-11-12 10-Q | Naji Gehchan | Chief Medical and Development Officer | Rule 10b5-1 | September 12, 2025 | April 1, 2026 | 106,250 | |
| 2025-08-12 10-Q | |||||||
| 2025-05-13 10-Q | |||||||
| 2024-11-13 10-Q | |||||||
| 2024-11-13 10-Q | Karen Walker | Chief Technology Officer | Rule 10b5-1 | August 24, 2024 | June 30, 2025 | 20,000 | |
| 2024-08-12 10-Q | |||||||
| 2024-08-12 10-Q | Dominic Borie | President, Research and Development | Rule 10b5-1 | June 3, 2024 | September 1, 2025 | 150,000 | |
| 2024-08-12 10-Q | Peter Maag | Chief Executive Officer and a Director | Rule 10b5-1 | June 3, 2024 | May 6, 2026 | 380,000 | |
| 2024-08-12 10-Q | Ryan Jones | Chief Financial Officer | Rule 10b5-1 | June 4, 2024 | December 31, 2025 | 74,929 | |
| 2024-08-12 10-Q | Rule 10b5-1 | November 9, 2005 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |